ArticleFrontiers in immunology2025
Application of a risk score model based on tyrosine-related genes in the prognosis and treatment of patients with lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine is associated with alterations in the tricarboxylic acid cycle in lung cancer, and exploring tyrosine-related genes (TRGs) has the potential to contribute to the construction of new sensitive prognostic biomarkers for patients with lung adenocarcinoma (LUAD). Method: Lung cancer prognosis model was constructed by Lasso Cox regression, univariate and multivariate COX regression, GSEA, TIDE. Potential drugs were screened and drug sensitivities analyzed by the pRRophetic software package. And the role of MYO6 in lung cancer was confirmed by experiments Results: We identified 7 TRG risk score models (ZFP3, MEAK7, MMUR1, GTF3C6, MYO6, MAPK1IP1L and VAX1) for the diagnosis and prognosis of patients with LUAD. ROC curves and the C-index suggested that the risk score had more reliable diagnostic significance and could more accurately predict the prognosis of LUAD patients. The nomogram model was constructed with risk scores, which can be used to predict an individual and visualize the correlation between the total score and the predicted outcome more intuitively. Additionally, it has an impact on immunotherapy efficacy, tumor mutation burden and drug sensitivity. In addition, high expression of myosin VI (MYO6) was related to tumor proliferation and metastasis Conclusion: In conclusion, the risk scores constructed from seven TRGs have great potential for survival prognosis, immunotherapy response and drug sensitivity. MYO6 plays an oncogenic role in promoting proliferation and metastasis in patients with LUAD, which provides a new theoretical basis for the diagnosis and treatment of LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.